📊 IDYA Key Takeaways
Is IDEAYA Biosciences, Inc. (IDYA) a Good Investment?
IDEAYA demonstrates exceptional revenue growth of 3024% YoY from early product commercialization, supported by a fortress balance sheet with $1.0B equity, zero debt, and $112.8M cash reserves. While currently unprofitable with -52% net margins and -$73.5M negative free cash flow, significantly improving per-share metrics (+61.9% EPS improvement YoY) signal meaningful progress toward profitability as commercial traction accelerates.
IDEAYA’s fundamentals show a step‑change in revenue but the business remains structurally loss‑making with negative free cash flow. A debt‑free, highly liquid balance sheet provides multi‑year runway to advance programs, while EPS loss has narrowed. However, profitability hinges on sustaining revenue (likely milestone/collaboration‑driven) and moderating R&D spend.
Why Buy IDEAYA Biosciences, Inc. Stock? IDYA Key Strengths
- Exceptional revenue growth (+3024% YoY) indicating successful early-stage product commercialization
- Fortress balance sheet with $1.0B stockholders equity and zero long-term debt obligations
- Strong liquidity position (11.34x current ratio) with $112.8M cash reserves enabling multi-year operational runway
- Significantly improving per-share economics (+61.9% EPS improvement YoY) despite flat net income
- Minimal financial leverage providing maximum operational flexibility during growth phase
- Exceptional liquidity (current ratio 11.34x; quick 11.34x)
- Debt‑free balance sheet with low liabilities and $1.02B equity
- Explosive revenue growth and improved EPS loss trajectory
IDYA Stock Risks: IDEAYA Biosciences, Inc. Investment Risks
- Deep operating losses (-$159.3M) and negative net margins (-52.0%) despite substantial revenue base
- Significant negative free cash flow (-$73.5M) creating approximately 1.5-year cash runway at current burn rate
- Unproven ability to achieve profitability at scale; cost structure may not leverage with revenue growth
- Biotech sector concentration risk with commercial success dependent on limited approved product portfolio and adoption
- Persistent operating losses (‑72.8% margin) and negative FCF (‑33.6% margin)
- Revenue quality/sustainability risk if milestone‑driven; gross margin N/A
- Ongoing cash burn may necessitate external financing if not offset by durable revenue
Key Metrics to Watch
- Operating expense leverage trajectory and path to operating profitability
- Operating cash flow inflection point and cash burn rate deceleration
- Product revenue growth sustainability and market adoption penetration rates
- Updated cash runway projections based on burn rate trends
- Operating cash flow (TTM) / burn rate
- Deferred revenue and collaboration vs recurring revenue mix
IDEAYA Biosciences, Inc. (IDYA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 11.34x current ratio provides a solid financial cushion.
IDYA Profit Margin, ROE & Profitability Analysis
IDYA vs Healthcare Sector: How IDEAYA Biosciences, Inc. Compares
How IDEAYA Biosciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is IDEAYA Biosciences, Inc. Stock Overvalued? IDYA Valuation Analysis 2026
Based on fundamental analysis, IDEAYA Biosciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
IDEAYA Biosciences, Inc. Balance Sheet: IDYA Debt, Cash & Liquidity
IDYA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: IDEAYA Biosciences, Inc.'s revenue has grown significantly by 683% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.96 indicates the company is currently unprofitable.
IDYA Revenue Growth, EPS Growth & YoY Performance
IDYA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $207.8M | -$30.4M | $-0.34 |
| Q3 2024 | N/A | -$27.4M | $-0.46 |
| Q2 2024 | N/A | -$27.9M | $-0.50 |
| Q1 2024 | N/A | -$23.6M | $-0.49 |
| Q3 2023 | $8.0M | $1.6M | $0.04 |
| Q2 2023 | $3.5M | -$22.1M | $-0.50 |
| Q1 2023 | $7.9M | -$14.0M | $-0.36 |
| Q3 2022 | $9.0M | $1.6M | $0.04 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
IDEAYA Biosciences, Inc. Dividends, Buybacks & Capital Allocation
IDYA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for IDEAYA Biosciences, Inc. (CIK: 0001676725)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IDYA
What is the AI rating for IDYA?
IDEAYA Biosciences, Inc. (IDYA) has a Combined AI Rating of BUY from Claude (BUY) and ChatGPT (HOLD) with 68% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IDYA's key strengths?
Claude: Exceptional revenue growth (+3024% YoY) indicating successful early-stage product commercialization. Fortress balance sheet with $1.0B stockholders equity and zero long-term debt obligations. ChatGPT: Exceptional liquidity (current ratio 11.34x; quick 11.34x). Debt‑free balance sheet with low liabilities and $1.02B equity.
What are the risks of investing in IDYA?
Claude: Deep operating losses (-$159.3M) and negative net margins (-52.0%) despite substantial revenue base. Significant negative free cash flow (-$73.5M) creating approximately 1.5-year cash runway at current burn rate. ChatGPT: Persistent operating losses (‑72.8% margin) and negative FCF (‑33.6% margin). Revenue quality/sustainability risk if milestone‑driven; gross margin N/A.
What is IDYA's revenue and growth?
IDEAYA Biosciences, Inc. reported revenue of $218.7M.
Does IDYA pay dividends?
IDEAYA Biosciences, Inc. does not currently pay dividends.
Where can I find IDYA SEC filings?
Official SEC filings for IDEAYA Biosciences, Inc. (CIK: 0001676725) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IDYA's EPS?
IDEAYA Biosciences, Inc. has a diluted EPS of $-1.28.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IDYA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, IDEAYA Biosciences, Inc. has a BUY rating with 68% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is IDYA stock overvalued or undervalued?
Valuation metrics for IDYA: ROE of -11.1% (sector avg: 15%), net margin of -52.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IDYA stock in 2026?
Our dual AI analysis gives IDEAYA Biosciences, Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IDYA's free cash flow?
IDEAYA Biosciences, Inc.'s operating cash flow is $-71.1M, with capital expenditures of $2.4M. FCF margin is -33.6%.
How does IDYA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -52.0% (avg: 12%), ROE -11.1% (avg: 15%), current ratio 11.34 (avg: 2).